<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Dziadziuszko, Rafal</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Targeted Therapies for NSCLC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Lung cancers are a heterogeneous group of diseases, and research during the past decade has improved our ability to effectively personalize therapy. This article discusses therapies in oncogene-driven lung cancers, including the emergence of effective targeted therapies in the era of genomics.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>